Trial · NCT03712917

Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine

NCT03712917, Not applicable, Completed, Ataturk University; results first posted 2020-01-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine. Trials, record NCT03712917. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03712917

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
NCT number: NCT03712917
Status: Completed
Phases: Not applicable
Enrollment: 120 participants, actual
Lead sponsor: Ataturk University
Conditions: Migraine
Interventions: Greater Occipital Nerve Block, Topiramate, Flunarizine
First posted: 2018-10-19
Last updated: 2020-01-21
Results first posted: 2020-01-21

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Visual Analog Scale	Post treatment 4 weeks	Range Pain 0-10, 0: No pain, 10: Worst Pain
Primary	Attack Frequencies	Post treatment 4 weeks	Number of headaches patients suffer in a month.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Visual Analog Scale	Post treatment 4 weeks		score on a scale	MEAN
PRIMARY	Attack Frequencies	Post treatment 4 weeks		headaches per month	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Visual Analog Scale	Greater Occipital Nerve Block	Pretreatment	8.1	Standard Deviation 1.0	score on a scale
Visual Analog Scale	Topiramate	Pretreatment	7.9	Standard Deviation 0.9	score on a scale
Visual Analog Scale	Flunarizine	Pretreatment	7.9	Standard Deviation 0.9	score on a scale
Visual Analog Scale	Greater Occipital Nerve Block	Posttreatment	5.9	Standard Deviation 1.6	score on a scale
Visual Analog Scale	Topiramate	Posttreatment	5.5	Standard Deviation 2.1	score on a scale
Visual Analog Scale	Flunarizine	Posttreatment	5.3	Standard Deviation 1.7	score on a scale
Attack Frequencies	Greater Occipital Nerve Block	Pretreatment	8.6	Standard Deviation 2.6	headaches per month
Attack Frequencies	Topiramate	Pretreatment	8.0	Standard Deviation 2.7	headaches per month
Attack Frequencies	Flunarizine	Pretreatment	8.0	Standard Deviation 2.4	headaches per month
Attack Frequencies	Greater Occipital Nerve Block	Posttreatment	3.3	Standard Deviation 1.0	headaches per month

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Greater Occipital Nerve Block	40
Overall Study	STARTED	Topiramate	40
Overall Study	STARTED	Flunarizine	40
Overall Study	COMPLETED	Greater Occipital Nerve Block	31
Overall Study	COMPLETED	Topiramate	32
Overall Study	COMPLETED	Flunarizine	31
Overall Study	NOT COMPLETED	Greater Occipital Nerve Block	9
Overall Study	NOT COMPLETED	Topiramate	8
Overall Study	NOT COMPLETED	Flunarizine	9

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Sedation	Nervous system disorders	Greater Occipital Nerve Block	0	40	0
other	Sedation	Nervous system disorders	Topiramate	0	40	0
other	Sedation	Nervous system disorders	Flunarizine	3	40	3
other	Fatique	Nervous system disorders	Greater Occipital Nerve Block	0	40	0
other	Fatique	Nervous system disorders	Topiramate	1	40	1
other	Fatique	Nervous system disorders	Flunarizine	0	40	0
other	paresthesia	Nervous system disorders	Greater Occipital Nerve Block	0	40	0
other	paresthesia	Nervous system disorders	Topiramate	1	40	1
other	paresthesia	Nervous system disorders	Flunarizine	0	40	0
other	memory difficulties	Nervous system disorders	Greater Occipital Nerve Block	0	40	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Greater Occipital Nerve Block	0	40
Total, all-cause mortality	Topiramate	0	40
Total, all-cause mortality	Flunarizine	0	40
Total, other adverse events	Greater Occipital Nerve Block	0	40
Total, other adverse events	Topiramate	4	40
Total, other adverse events	Flunarizine	3	40
Total, serious adverse events	Greater Occipital Nerve Block	0	40
Total, serious adverse events	Topiramate	0	40
Total, serious adverse events	Flunarizine	0	40

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
1454403	BACKGROUND	PubMed
15096395	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03712917

GET https://conductscience.org/api/trials/v1/NCT03712917/registered

API reference For AI assistants